Systemic therapy use, however, can be dependent on molecular characterization, such as HER2 expression status and mutational status of ERBB2, PIK3CA, AKT1, PTEN, and ESR1 [4,16], particularly in the primary tumor. This evidence concerns the gene ERBB2 and neoplasm.